Menu
Back to Journals » Cancer Management and Research » Volume 13
Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum]
Tai Y, Zhang LH, Gao JH, et al. Cancer Manag Res. 2019;11:2831–2848.
The authors have advised due to an error that occurred inadvertently at the time of figure assembly, Figure 7A on page 2842 is incorrect. The correct Figure 7 is shown in Download Article.
Figure 7 Celecoxib up-regulated E-cadherin via inhibition of COX-2–PGE2–EP2–p-Akt/p-ERK in Bel7402 cells. Compared with DMSO-treated and empty plasmid-transfected Bel7402 cells, overexpression of COX-2 by using COX-2 ORF plasmid induced reduction of E-cadherin expression and increase of p-Akt and p-ERK expression determined by IF (A) and Western blot (D). Compared with DMSO-treated cells, the expression of E-cadherin quantified by IF (B and C) and Western blot (E and F) was upregulated by EP2 inhibitor AH6809, Akt inhibitor MK2206, and ERK inhibitor AZD6244, but down-regulated by PGE2, which could be reversed by AH6809. Meanwhile, the expression of p-Akt and p-ERK was significantly suppressed by treatment with celecoxib and AH6809 but was enhanced by treatment with PGE2, which could be inhibited by AH6809 (E). Scale bar =50 μm for IF.
The authors apologize for these errors and advise they do not affect the interpretation of data or the conclusion of the study.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.